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HIV-associated nephropathy is a late, not early, manifestation Human immunodeficiency virus–associated nephropa-
of HIV-1 infection. thy (HIVAN) is the single most common cause of chronic
Background. Human immunodeficiency virus–associated renal disease in HIV-1 seropositive patients [1–4]. Thenephropathy (HIVAN) can be the initial presentation of HIV-
incidence of HIVAN continues to increase [5], and we1 infection. As a result, many have assumed that HIVAN can
have calculated from the U.S. Renal Data System databaseoccur at any point in the infection. This issue has important
implications for appropriate therapy and, perhaps, for patho- that HIVAN is now the third leading cause of renal failure
genesis. Since the development of new case definitions for in African Americans between the ages of 20 and 64 [6].
acquired immunodeficiency syndrome (AIDS) and better tools Without a major change in the acquired immunodeficiencyto assess infection, the relationship of HIVAN to the time
syndrome (AIDS) epidemic in general, nephrologists canof AIDS infection has not been addressed. In this study, we
anticipate that increasing numbers of HIVAN patientsreassessed the stage of infection at the time of HIVAN diagnosis
in 10 patients, and we reviewed all previously published cases will be presenting to them in the future [6]. HIVAN is
applying the new case definitions to assess stage of infection. morphologically defined by a collapsing form of focal seg-
Methods. HIVAN was confirmed by kidney biopsy in HIV mental glomerulosclerosis, glomerular visceral epithelialseropositive patients with azotemia and/or proteinuria. CD41
cell hypertrophy, and prominent tubulointerstitial infil-cell count and plasma HIV-1 RNA copy number were mea-
tration with edema, fibrosis, and microcystic tubule dila-sured. We also reviewed all published cases of HIVAN to
determine if AIDS-defining conditions, by current Centers for tation [7, 8]. In the absence of specific therapy, HIVAN
Disease Control definitions, were present in patients with progresses to end-stage renal failure within weeks to
biopsy-proven HIVAN. months [9–13].Results. Twenty HIV-1 seropositive patients with protein-
End-stage renal disease patients who are not infecteduria and an elevated creatinine concentration were biopsied.
with HIV have a median survival of approximately sixHIVAN was the single most common cause of renal disease.
CD41 cell count was below 200/mm3 in all patients with HI- years [14]. Median survival of new HIV seroconverters is
VAN, fulfilling Centers for Disease Control criteria for an 10 years [15], yet patients with HIVAN who come to dialy-
AIDS-defining condition. HIV-1 plasma RNA was detectable sis have a mortality that approaches 50% per year [16].in all patients with HIVAN. In reviewing previous reports, an
In a review of 102 patients with biopsy-proven HIVAN,AIDS-defining condition was present in virtually all patients
mortality rates at one and three years were 50% andwith HIVAN.
Conclusion. HIVAN develops late, not early, in the course 68%, respectively [17]. In this report and others, mortal-
of HIV-1 infection following the development of AIDS. This ity has been especially high when the underlying HIV
likely accounts for the poor prognosis noted in previous publi- infection becomes symptomatic or progresses to an AIDS-cations and has implications for pathogenesis. In addition,
defining condition [2, 3, 16, 18]. Prior to the era of potent,given the detectable viral RNA levels, highly active antiretrovi-
combination antiretroviral therapy, mortality rates inral therapy is indicated in HIVAN. Highly active antiretroviral
therapy may improve survival as well as alter the natural history AIDS patients without renal disease were similar to
of HIVAN. those of patients with HIVAN—50% at one year and
70% to 85% at three years [19, 20]. These data suggest
that patients with HIVAN have a clinical progression
Key words: AIDS, end-stage renal failure, highly active antiretroviral
that is essentially equivalent to seropositive patients whotherapy, HIV-associated nephropathy, focal segmental glomeruloscle-
rosis, virus. develop an AIDS-defining condition.
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Table 1. Serum creatinine, protein excretion and CD41 cell countin the course of HIV-1 infection [2–4]. Two hypotheses
in human immunodefiency virus-1 (HIV-1) seropositive patients
can be generated by these observations: (a) The develop- with HIV-associated nephropathy (HIVAN) and other forms
of renal diseasement of nephropathy, or the progression to end-stage
renal disease, in some way impacts the natural history Creatinine Urinary protein CD4
of HIV-1. (b) HIVAN is, in essence, an AIDS-defining Patient # Diagnosis mg% mg/24 hrs cells/mm3
condition that presents late in the course of HIV infec- 1 HIVAN 5 4700 20
2 HIVAN 2.5 6100 10tion and has a prognosis similar to any seropositive pa-
3 HIVAN 1.6 1100 0tient that develops AIDS.
4 HIVAN 2.2 1100 200
In this study, we address these exclusive hypotheses 5 HIVAN 2 7500 30
6 HIVAN 1.4 5300 0by analyzing CD41 cell counts and viral burden in sero-
7 HIVAN 3.5 12000 40positive patients with renal disease. We find that an
8 HIVAN 3.3 3700 160
AIDS-defining condition, as currently defined by the 9 HIVAN 1.8 1500 120
10 HIVAN 5.6 2500 20Centers for Disease Control [21], predates the diagnosis
Mean 2.9 4550 60of HIVAN in all patients. We conclude that HIVAN
SE 0.5 1082 23
usually develops as a late complication of HIV-1 infec-
11 Amyloid 5 2000 150tion. This is an important observation for defining an 12 Acute GN 1.7 970 160
optimal treatment(s) for patients with HIVAN, and it 13 Min change 2.2 1300 10
14 Diabetes 4 4600 270may have implications for disease pathogenesis.
15 Focal GN 2 1800 90
16 Global Scl 1.8 2900 0
17 Diabetes 2 4600 60
METHODS 18 Cryoglob 1.5 9800 110
19 Cryoglob 1.8 1600 190Human immunodeficiency virus-1 seropositive patients
20 Acute GN 2 770
were eligible for enrollment into an Institutional Review Mean 2.4 3286 181
SE 0.4 928 70Board (IRB)-approved protocol in which the diagnosis
Abbreviations are: GN, glomerulonephritis; Min, minimal; Scl, sclerosis; Cryo-of HIVAN was confirmed by a percutaneous kidney
glob, cryoglobulinemia.biopsy. The patient population consisted of those referred
for nephrologic consultation. Biopsies were performed
when HIVAN was suspected based on the clinical crite-
ria: urinary protein excretion exceeding 1 g/24 hr or the Table 2. Plasma viral RNA levels (copies/ml) in HIVAN
presence of azotemia not attributable to acute renal fail-
Patient # Diagnosis Copies/ml plasma
ure. Renal biopsies were processed for light microscopy,
1 HIVAN 1.2 3 103immunofluorescence, and electron microscopy according 2 HIVAN 2.3 3 105
to standard techniques. HIVAN was diagnosed by the 3 HIVAN 3.6 3 106
4 HIVAN 7.5 3 102presence of focal segmental glomerulosclerosis com-
5 HIVAN 1.2 3 103bined with visceral epithelial cell hypertrophy, glomeru- 6 HIVAN 1.3 3 106
lar collapse, and interstitial infiltrates accompanying mi- 8 HIVAN 5.8 3 103
10 HIVAN 6.2 3 104crocystic tubule dilation [1]. Plasma HIV-1 RNA was
measured at the time of kidney biopsy using a commer-
cially prepared quantitative reverse-transcriptase poly-
merase chain reaction assay (Amplicor; Roche Diagnos-
were not different between patients with and withouttic Systems, Branchburg, NJ, USA). Measurements of
HIVAN. Nine patients with HIVAN and eight patientsCD41 cell counts were performed in the clinical immu-
with other kidney diseases were African American, andnology laboratory by immunophenotyping by flow cy-
the remaining were Hispanic. The age range was 24 totometry using a Becton Dickinson FACScan (San Jose,
58 years and was similar in both groups. In those withCA, USA).
HIVAN, 50% were asymptomatic with regard to their
HIV-1 infection and had suffered no opportunistic infec-
RESULTS tions. By criteria prior to 1993, they would have been
considered to have asymptomatic or early infection. ByOver the course of 18 months between 1995 and 1997,
20 seropositive patients with chronic renal disease con- current criteria, these patients had AIDS because CD41
counts were less than 200 cells/mm3.sented to biopsy. Their findings are summarized in Table 1.
HIVAN was diagnosed in half of all patients, whereas At the time of biopsy, five patients with HIVAN were
taking antiretrovirals, but none were receiving proteasevarious other causes of parenchymal disease were found
in the remaining group. Mean values for serum creatinine, inhibitors. As shown in Table 2, plasma HIV-1 RNA
was detectable in seven patients, ranging from 7.5 3 10224-hour urinary protein excretion, and CD41 counts
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Table 3. AIDS defining conditions in patients with in the other two [26, 27]. In retrospect, it is most likely
biopsy-proven HIVAN
that these patients were late in their disease. Of the
Author N Patients Stage of HIV infection several patients in our series who were asymptomatic or
Rao et al, 1984 11 All with opportunistic infection whose nephropathy was the initial manifestation of HIV-1
Carbone et al, 1989 26 Low T4 count in all patients infection, all were markedly immunosuppressed. Our re-
Strauss et al, 1989 5 Low CD41
view indicates that this has been consistent in virtuallyLangs et al, 1990 15 All patients with clinical AIDS, ARC
Kimmel et al, 1996 18 CD41 cell count ,200/mm3 except all previously reported cases of HIVAN. Additional indi-
one patient (235 cells/mm3) rect evidence supports the hypothesis that HIVAN is a
Smith et al, 1996 20 Highest CD41 count 160 cells/mm3
late complication of HIV-1 infection. The average timeBurns et al, 1997 20 15 with CD41 ,200 cells/mm3 liter
Lardi et al, 1997 102 Mean CD41 cell count 122 cells/mm3 from seroconversion to the AIDS-defining condition of
a CD41 count less than 200 cells/mm3 or an opportunisticData are from 9–13, 17, 23, 24.
infection is 8 to 10 years [15]. If HIVAN occurred early
in HIV-1 infection, one would expect some patients to
have a prolonged disease-free interval, but this has not
to more than 3.6 3 106 copies. In three patients with been reported.
HIVAN, HIV-1 RNA was relatively low (less than 2 3 The degree of immunosuppression present in patients
103) but was easily detectable. There was no correlation with HIVAN is associated with a poor prognosis and an
between plasma HIV-1 RNA levels, antiretroviral treat- extremely high risk of death from AIDS. This risk may
ment, or serum creatinine, but the number studied was explain the high mortality rate of HIVAN reported by
too small to reach a valid conclusion. most authors. Many of our patients were not receiving
We then applied current AIDS case definitions to all or were not taking an optimal antiretroviral regimen.
previous studies of HIVAN in which CD4 counts were The current standard of care for patients with low CD4
available. Those reports are summarized in Table 3. There cell counts and detectable viral burden is highly active
were no serologic markers for HIV-1 when HIVAN was antiretroviral therapy (HAART) [25]. Because virtually
originally described in 1984 [12, 22], and therefore, all all patients with HIVAN have low CD4 counts and/or
patients in the original report had advanced AIDS with detectable viral burden, HAART should be part of the
opportunistic infections. Of the subsequent studies, we standard therapeutic approach in HIVAN. In the past,
found six in which individual CD4 counts were reported failure to treat these patients aggressively with antiret-
[9–11, 13, 23, 24]. Together with our patients, these re- roviral therapy may be related, in part, to misconceptions
ports comprise 114 patients with HIVAN. Although regarding the stage of HIV-1 infection as well as insuffi-
many patients were asymptomatic in terms of their HIV-1 cient information as to the use of antivirals in patients
infection, CD41 counts were less than 200 cells/mm3 in with impaired renal function. Dose adjustments are re-
all but six patients. quired for many of the reverse transcriptase inhibitors,
whereas the protease inhibitors are primarily cleared by
the liver and require no dose adjustments [28, 29]. De-
DISCUSSION spite complicating factors, the presence of HIVAN should
Following HIV-1 infection, CD41 cell depletion re- not exempt a patient from receiving HAART.
sults from ongoing viral replication and occurs late in We have shown that the overwhelming majority of
the natural history of the disease [25]. Recognizing that patients develop AIDS before HIVAN is diagnosed. We
individuals with CD41 cell counts less than 200 cells/ believe that the high mortality rate is understandable in
mm3 are at high risk for HIV-1–related morbidity and the context of advanced HIV-1 infection and that the
mortality, the Centers for Disease Control revised the treatment for HIVAN is incomplete in the absence of
case definition for AIDS in 1993. As reported by several specific therapy aimed at reducing viral replication. Be-
groups prior to 1993, HIVAN could present as the initial cause, by design, our study sampled only those patients
manifestation of HIV-1 infection in patients who were with clinically recognizable nephropathy, we cannot
otherwise asymptomatic [2, 12, 18]. This provided the make a definitive statement as to whether markers of
supportive evidence for the current clinical suggestion early nephropathy may have been present prior to the
that it is not unusual for HIVAN to occur early in the onset of AIDS in our patients and in others. In two of our
course of HIV-1 infection [3, 4]. patients in whom prior determinations could be made,
We explored whether the patients reported to have proteinuria developed after the onset of clinical AIDS.
asymptomatic early disease would have fallen into to- Sufficient data were not available to render a valid con-
day’s case definition for AIDS. In seven patients whose clusion in the others. Thus, important questions remain
HIVAN was reported as the initial clinical manifestation to be answered: Are certain lesions a precursor to HI-
of HIV-1 infection, opportunistic infections developed VAN? Do any clinical markers predict early HIVAN?
Do early markers develop prior to the onset of AIDS?within six months in five patients and within 13 months
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